Table 4.
PPAR expression in some cancers in comparison with corresponding normal cells/tissues.
| PPAR Isoform | Cancer Type | Change in the Expression | References |
|---|---|---|---|
| γ | Colorectal Carcinoma (human specimens) |
Decrease | [157,158] |
| Gastric Carcinoma (human specimens) |
Decrease | [159] | |
| Nonmedullary Thyroid Carcinoma (human specimens) |
Decrease | [160] | |
| Cervical Carcinoma (human specimens) |
Decrease | [161] | |
| Esophageal Cancer +(human specimens) |
Decrease | [162] | |
| Prostate Carcinoma (human specimens) |
Increase | [163] | |
| Colorectal Carcinoma (human specimens) |
Decrease | [164] | |
| α | Colorectal Carcinoma (CaCo-2 cells) |
Increase | [165] |
| Ampullary Cancer (human specimens) |
Increase | [166] | |
| Lung Cancer(mouse model) | Decrease | [167] | |
| β/δ | Prostate Carcinoma (human specimens; DU145, PC3, LNCAP, VCAP, C4-2, 22RV1 cell lines) |
Decrease | [168] |
| Melanoma (human specimens; A375 cell line) |
Increase | [169] | |
| NSCLC (human specimens; H358, H441, H23, A549 cell lines) |
Increase | [170] | |
| Thyroid Cancer (human specimens) |
Increase | [171] | |
| Ovarian Cancer (mouse model) |
Increase | [172] | |
| Colorectal Carcinoma (human specimens) |
Increase | [164] |